Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Research Coverage Started at LADENBURG THALM/SH SH

Research analysts at LADENBURG THALM/SH SH initiated coverage on shares of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) in a note issued to investors on Wednesday, June 19th, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $9.00 price target on the stock. LADENBURG THALM/SH SH’s price objective suggests a potential upside of 163.16% from the stock’s current price.

Several other research firms have also issued reports on ARMP. Zacks Investment Research upgraded GALP ENERGIA SG/ADR from a “sell” rating to a “hold” rating in a research report on Monday, May 27th. HC Wainwright set a $7.00 target price on Armata Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, May 23rd.

NYSEAMERICAN:ARMP traded down $0.05 during mid-day trading on Wednesday, hitting $3.42. 18,100 shares of the company’s stock traded hands, compared to its average volume of 71,564. Armata Pharmaceuticals has a 12 month low of $2.10 and a 12 month high of $19.18.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last announced its earnings results on Monday, May 6th. The company reported ($1.54) earnings per share for the quarter, meeting the consensus estimate of ($1.54).

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains.

Further Reading: Penny Stocks

Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.